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OBJECTIVES The aim of this study was to evaluate whether thromboxane inhibition can favorably affect
renal perfusion and clinical conditions in patients affected by severe heart failure.
BACKGROUND The renal formation of the vasoconstrictor thromboxane A2 (TxA2) is increased during
cardiac failure.
METHODS By oral administration of picotamide (a renal TxA2 synthase and TxA2/prostaglandin H2
receptor inhibitor), we blocked renal TxA2. Fourteen patients in New York Heart Association
functional class IV were studied according to a randomized, double-blinded, cross-over
design. Each of the two eight-day periods of testing was preceded by a three-day period
during which certain vasoactive medications were stopped.
RESULTS Daily 24-h total urinary thromboxane B2 (TxB2), the stable metabolite of TxA2, dropped at
the end of picotamide treatment (p  0.01 vs. baseline). Compared with placebo, effective
renal plasma flow and the glomerular filtration rate increased (p  0.01 and p  0.05,
respectively), thus leading to a significant decrease in the filtration fraction (p  0.01). Renal
vascular resistance decreased consistently (p 0.01). In all patients, picotamide treatment was
associated with an increase in diuresis and natriuresis (p  0.001 vs. baseline). Plasma
creatinine decreased (p  0.05 vs. baseline). Patients also showed improvement in several
clinical parameters, including a significant decrease in both pulmonary and venous pressure (p
 0.01 vs. baseline).
CONCLUSIONS These results indicate that renal thromboxane formation plays an important role in renal
vascular resistance in patients with severe heart failure, such as those described in the present
study. Inhibition of TxA2 improves renal hemodynamics and kidney function and favorably
affects indexes of cardiac performance. (J Am Coll Cardiol 2003;42:133–9) © 2003 by the
American College of Cardiology Foundation
Chronic congestive heart failure (CHF) is characterized by
the activation of neurohormonal vasoconstrictive pathways.
These include the sympathetic nervous system, the renin-
angiotensin system, vasopressin, and endothelin (1–4). The
neurohormonal effects contribute to maintaining effective
plasma volume by stimulating the tubulo-glomerular feed-
back mechanism (2). This mechanism is associated with a
progressive decline in renal plasma flow and an increase in
the filtration fraction (FF) due to selective constriction of
the efferent arterioles (5–7) to preserve glomerular filtration.
The increased formation of vasoconstrictor mediators is
associated with enhanced formation of systemic and renal
vasodilative factors, such as cardiac natriuretic peptides and
renal prostaglandin (PG)E2 and PGI2 (1,8). Renal PGE2
and PGI2 counteract vasoconstriction, hence contributing
to the maintenance of intrarenal circulatory homeostasis (9).
A progressive increase in renal production of vasoconstrictor
eicosanoids, such as PGF2 and thromboxane A2 (TxA2),
occurs in the more advanced stages of CHF (10). This
increase most likely results in a decrease in renal blood flow,
as suggested by experimental studies (11–13). Thromboxane
A2 promotes tubulo-glomerular feedback in microperfused
single-nephron preparations (14). It causes renal vasocon-
striction when injected in animals (11), thus resulting in
increased sodium and water retention.
Under physiologic conditions, TxA2 renal production in
humans is low and does not play any role in renal hemo-
dynamics (15). In pathophysiologic conditions such as
CHF, renal function can remarkably worsen in the presence
of large and persistent increases in renal TxA2 formation
(10). To investigate renal TxA2 formation and its role in
renal hemodynamics in patients with severe CHF, we used
a TxA2 synthase and TxA2/PGH2 receptor inhibitor called
picotamide (16). Several clinical trials have shown that
picotamide can effectively block TxA2 activity, thus result-
ing in good clinical effects (17–19).
METHODS
Patient selection. We investigated 14 patients in New
York Heart Association (NYHA) functional class IV (10
males and 4 females; mean age 70  10 years). The
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demographic and clinical characteristics of the patients are
reported in Table 1. Patients enrolled in the study had
chronic CHF due to idiopathic dilated cardiomyopathy (n
 3), ischemic dilated cardiomyopathy (n  10), and mitral
regurgitation (n  1). The patients with ischemic dilated
cardiomyopathy had a previous (more than six months
before the start of the study) myocardial infarction; none of
them reported any episodes of angina during testing or for
six months before the start of the study. No patients had
clinically detectable edema or pulmonary rales. Patients who
were enrolled in this study required hospitalization due to
the inability for home treatment of NYHA functional
class IV CHF. Because aspirin and nonsteroidal anti-
inflammatory drugs can interfere with the effects of picota-
mide, patient selection criteria were also based on the
exclusion of the use of aspirin or angiotensin-converting
enzyme (ACE) inhibitors.
Patients with diabetes, liver or renal disease, malignan-
cies, or serum creatinine levels 2.0 mg/dl were excluded
from the study. The investigation followed the principles of
the Declaration of Helsinki. All patients gave their in-
formed, written consent to participate in the study after a
clear and thorough explanation of the program had been
presented.
Study design. The study was designed as a randomized,
double-blinded, placebo-controlled, cross-over study. The
patients were treated with digitalis, diuretics, and nitrates.
Before hospitalization, two patients with atrial fibrillation
had been on oral anticoagulants; during the study, they
continued this treatment (international normalized ratio 2.5
to 3.0). Administration of digitalis, vasodilators, and diuret-
ics was continued at the pre-established optimal dosage.
Given that ACE inhibition can stimulate prostaglandin and
thromboxane formation via bradykinin activation (20,21),
ACE inhibitor administration was discontinued during the
48 h before the beginning the study and during the study.
To prevent any possible deterioration in the clinical picture
due to the withholding of ACE inhibitors, the enrolled
patients were kept under strict, close, continuous clinical
surveillance during the whole trial period. Only those
patients whose conditions had remained stable after the first
12 h after ACE inhibitor discontinuation were admitted
into the study. Patients remained under surveillance during
the entire period of hospitalization until the end of the
study. Initially, 20 patients had been selected, but only 14
were admitted into the study (6 patients had shown signs of
instability during the 12-h pretreatment evaluation period).
To obtain an index of the modifications of the patients’
clinical status (during testing), we evaluated the variations in
tachycardia, breathlessness, and the occurrence of pulmo-
nary rales and clinically detectable edema (before, during,
and after the testing period). Evaluation was carried out
twice by two cardiologists, neither of whom had any
knowledge of the laboratory results, tests carried out, and/or
treatment. During the total hospital period, the subjects
were kept on a daily diet that contained 100 mmol of
sodium chloride and 60 to 80 mmol of potassium. Dietary
compliance with sodium intake was checked by measuring
urinary sodium. Daily fluid intake was checked so that a
constant water balance was maintained during the three-day
pretreatment period. Patients received two tablets per day of
either placebo or picotamide (600 mg, orally). After eight
days of treatment, the patients underwent a three-day
washout period before crossing over to the other treatment
arm for a second eight-day period. The urine sample from
the first day of the two eight-day periods was used to
determine baseline values. On the second, fourth, sixth, and
eighth days of both treatment periods, serum and urinary
electrolytes, 24-h urinary volume, and 24-h urinary throm-
boxane excretion were measured. On the eighth day of both
treatment periods, we studied renal hemodynamics. This
experimental design allowed for a comparison between the
treatment and placebo effects on renal hemodynamic pa-
rameters, without the need to expose the patients to any
additional radioisotopic clearance studies.
Systemic hemodynamic parameters. Blood pressure and
heart rate were recorded on an average of six times a day (at
6:00, 8:00, and 12:00 AM and 4:00, 8:00, and 12:00 PM).
Results were used as an index of the 24-h study period.
They were also used to control levels of hypotension (a
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
ERPF  effective renal plasma flow
FF  filtration fraction
GFR  glomerular filtration rate
mPAP  mean pulmonary artery pressure
NYHA  New York Heart Association
PG  prostaglandin
RIA  radioimmunoassay
RVR  renal vascular resistance
TxA2  thromboxane A2
TxB2  thromboxane B2
UCr  urinary creatinine
Table 1. Patient Characteristics and Medications
Etiology
Ischemic heart disease (%) 10 (71)
Dilated cardiomiopathy (%) 3 (21)
Valvular heart disease (%) 1 (8)
Baseline hemodynamic characteristics
EF on echocardiography (%) 27  10
Mean BP (mm Hg) 94.3  11.4
HR (beats/min) 78.5  7.3
Medications throughout the study
Digoxin 0.125–0.25 mg once or twice daily 14
Furosemide 25–125 mg once or twice daily 14
Canrenoate potassium 100 mg orally twice daily 7
Medications discontinued before admission
Captopril 25 mg twice daily 4
Ramipril 2.5–5 mg twice daily 4
Data are presented as the number (%) of patients.
BP  blood pressure; EF  ejection fraction; HR  heart rate.
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symptomatic sudden and/or persistent decline in arterial
systolic blood pressure 105 mm Hg) and/or orthostatic
hypotension (i.e., a drop in systolic blood pressure 20 mm
Hg or in diastolic blood pressure 10 mm Hg) (22). Mean
pulmonary artery pressure (mPAP) was measured by Dopp-
ler echocardiography on day 0 before the start of each
eight-day period and on days 2, 4, 6, and 8 of each testing
period. In one patient not showing tricuspid insufficiency,
the pulmonary acceleration time was used to estimate
mPAP, given that the two have been shown to be directly
and strongly correlated (23). If tricuspid regurgitation was
present, the atrioventricular pressure gradient was used to
estimate mPAP, as described elsewhere (24). Venous pres-
sure was obtained directly (25) through an antecubital vein.
Renal excretory function. Blood urea nitrogen, serum
creatinine, serum and urinary sodium, and water excretion
were monitored every other day throughout the hospital
period. Urinary and serum sodium and potassium were
measured by using a flame photometer (Instrumentation
Laboratory, Lexington, Massachusetts).
Renal hemodynamics. At the end of the two periods of the
study, two radioisotopes were rapidly injected into an
antecubital vein with a 20-gauge needle, (iodine-125
[iothalamate] and iodine-131 [hippurate], both at a dose of
1 Ci/kg in a total volume of 9 ml). Six-milliliter blood
samples were withdrawn from the other antecubital vein at
2, 5, 10, 15, 30, 45, 60, 90, 120, 150, and 180 min after
isotopic injection. Blood samples were immediately centri-
fuged and a 3-ml plasma volume was measured for 5 min
with a gamma ray, well-counter spectrometer (Packard
Instrument Company, Palo Alto, California). Effective
renal plasma flow (ERPF) and the glomerular filtration rate
(GFR) were measured according to the methods described
by Sapirstein et al. (26). The obtained values were normal-
ized to a standard body surface area of 1.73 m2.
Urinary TxB2 measurement. Immediately after collection,
the urine was frozen and stored at 20°C until extraction
and purification procedures could be carried out. Renal
thromboxane B2 (TxB2) was measured by radioimmunoas-
say (RIA), as reported elsewhere (27). A tritium tracer RIA
was performed after allowing four to five months for the
radioactivity of the iodine-125 and -131 in the urine to
decay to background levels so as not to interfere with the
TxB2 RIA (28). Furthermore, before processing the urine
for RIA, each sample was placed in a gamma counter to rule
out any residual radioactivity. The data are expressed as ng/g
of 24-h urinary creatinine to normalize the detected values
according to the changes in renal function.
Statistical analysis. Continuous variables are expressed as
the mean value  SD. Discrete variables are expressed as
percentages. Comparisons between groups in basal condi-
tions were performed by using the Student t test. Before
analyzing the effects of the treatments on the different
clinical parameters examined, we compared the baseline
values with those obtained after the washout period, at the
beginning of the second part of the study. We first tested for
the presence of any differences within the same group, then
between groups with the paired t test and Student t test,
respectively. Given the lack of any dissimilarity (data not
shown), we performed a general linear model for repeated
measures to assess the effects of picotamide and placebo;
patient data were pooled according to treatment. Compar-
isons between each observation time within each treatment
group were performed in the same model specifying that the
baseline value was reference one and testing for the presence
of any statistically significant differences at days 2, 4, 6, and
8 (“simple” method) (29). Finally, we searched for differ-
ences between groups at each step of the study by using the
Student t test. A value of p  0.05 was considered
statistically significant. Given that 20 patients were initially
selected, but only 14 were admitted to the study after ACE
inhibitor suspension, we performed a retrospective power
analysis to evaluate whether the sample size was appropriate.
Assuming a mean value of TxB2 excretion of 900  122
ng/24 h for the 14 subjects enrolled, we built a model with
a two-tailed alpha level of 0.05, obtaining a precision in
estimating a difference in the population of 67 ng/24 h.
According to this estimate, for the difference of 468 ng/24
h in TxB2 excretion observed in the study, the power was
99.9%.
RESULTS
Effects of placebo administration. No adverse clinical
events or severe hypotension occurred during placebo ad-
ministration. During placebo administration, no change was
found in urinary TxB2 excretion (926  154 vs. 878  126
ng/g urinary creatinine [UCr]/24 h [first vs. eighth day], p
NS) (Fig. 1). Because renal and hemodynamic parameters
at baseline were similar both before treatment and in the
placebo periods, the three-day washout period appeared
sufficient to abolish the effects of picotamide. There were
not significant changes during the eight days on placebo.
Effects of picotamide treatment. A significant decrease in
urinary TxB2 was observed during the period of active
treatment (p  0.001) (Fig. 1). By the sixth day, urinary
TxB2 significantly dropped with respect to baseline (557 
138 vs. 900  122 ng/g UCr/24 h; 38.2%; p  0.01) and
reached its minimum on the eighth day of picotamide
treatment (432  117 vs. 900  122 ng/g UCr/24 h;
52.1%; p  0.01). Moreover, compared with placebo, a
significant decrease in urinary TxB2 was observed on the
sixth day (557  138 vs. 893  148 ng/g UCr/24 h;
37.7%; p  0.01) and on the eighth day of picotamide
treatment (432  117 vs. 878  126 ng/g UCr/24 h;
50.8%; p  0.01) (Fig. 1).
The modifications in thromboxane excretion were ac-
companied by significant changes in renal hemodynamics,
as shown in Figure 2. When comparing active treatment
with placebo treatment, picotamide administration in-
creased ERPF (31.4%, p  0.002) more than GFR
(7.9%, p  0.05 vs. placebo), thus leading to a reduction
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in FF (16%, p  0.01 vs. placebo). The overall renal
vascular resistance (RVR) decreased substantially (26.8%,
p  0.01 vs. placebo) (Fig. 2).
Table 2 reports the effect of active treatment on the
different parameters assayed. We noted in all patients a
decrease in both mPAP (20.6% vs. baseline, p  0.001)
and venous pressure (37.5%, p  0.01); this effect was
associated with clinical improvement, as indicated by a reduc-
tion in symptoms and increased sodium and water excretion.
Blood pressure did not vary during treatment, whereas the
heart rate significantly decreased. Picotamide treatment re-
sulted in clinical improvement leading to dyspnea reduction
and a decrease in tachycardia. Body weight significantly de-
creased on day 8 (3.5%, p  0.01 vs. day 1) of picotamide
treatment. No bleeding, hypotension, or other adverse
clinical events occurred during picotamide administration.
DISCUSSION
Thromboxaneinhibitionbypicotamideandrenalfunction.
In severe CHF, picotamide administration inhibited renal
thromboxane production in our patients who were not
exposed to beta-adrenergic blockade or angiotensin activity
suppression. The inhibition of renal thromboxane was
consistent with the drop in urinary TxB2, which is a
metabolite of renal TxA2 formation and not of platelet
TxA2 (30). Blockade of the renal effects of TxA2 led to a
partial recovery of renal hemodynamics, as indicated by the
31.4% increase in ERPF and 26.8% decline in RVR. The
renal resistance represents a very important part of total
peripheral vascular resistance, and its increase occurs soon
during the onset of CHF, thus leading to augmentation of
the cardiac work load. The increases in ERPF and GFR
following renal TxA2 inhibition most probably indicate that
the exaggerated TxA2 release in CHF participates in con-
striction of the renal resistance vessels and likely with
selective activity on afferent arterioles. This interpretation is
in agreement with a recent study providing evidence that the
afferent glomerular arteriole is the vascular segment that is
preferentially constricted by TxA2 (12). Inhibition of TxA2
can lead to renal vasodilation, even in the absence of ACE
inhibitors, highlighting the importance of the overproduc-
tion of renal thromboxane in the pathophysiology of CHF.
The effects of picotamide were investigated in a cross-over
experimental design where all patients were under con-
trolled daily sodium intake, and the therapy remained
unmodified during the whole study. The only variable was
picotamide versus placebo administration. The lack of
variations in renal function during placebo and the hemo-
dynamic changes observed after picotamide administration
should most probably not be interpreted as regression to the
mean but most likely as real modification and improvement.
The improvement in renal function appeared to be
related to the drop in pulmonary artery pressure and venous
pressure, both associated with inhibition of renal thrombox-
ane activity. The functional effects of TxA2 inhibition
became evident on the eighth day of picotamide adminis-
tration. This latency seems to be dependent on the cumu-
lative activity peculiar to this drug (18).
TxA2 and renal pathophysiology in heart failure. In
CHF, sympathetic activation and enhanced activity of the
renin-angiotensin system, as well as vasopressin, play a
major role in maintaining perfusion pressure and blood
volume (2). An increase in renal formation of vasodilating
PGE2 and PGI2 occurs in the early stages of heart failure (8)
and can modulate the effects of vasoconstrictor mediators
(1,9). This increase in vasodilating eicosanoid formation
helps to sustain adequate renal glomerular filtration (1).
With the progressive reduction in renal blood flow in the
Figure 1. Urinary thromboxane B2 (UTxB2) levels (ng/g UCr/24 h) during the two treatments: placebo (open bars) and active treatment (hatched bars).
*p  0.01 vs. day 6 of placebo; °p  0.01 vs. day 8 of placebo; §p  0.01 vs. baseline.
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advanced phases of CHF (i.e., patients in NYHA functional
class III and especially class IV), TxA2 formation is en-
hanced (10), thus increasing the RVR. The increased TxA2
formation results in the upset of the fine balance between
renal vasoconstrictor and vasodilating systems. The inhibi-
tion of TxA2 activity causes an increase in ERPF with
decrease in RVR, resulting in enhanced water and sodium
excretion. Furthermore, the inhibition of TxA2 synthesis
augments the availability of arachidonic acid, which is used
for the synthesis of vasodilating PGs (31,32). In addition to
its influence on renal hemodynamics, TxA2 can potentiate
tubulo-glomerular feedback by activating the sensory com-
ponent in the macula densa (32).
In summary, the favorable effects of TxA2 inhibition on
renal function in patients with advanced CHF may be the
consequence of three coexisting and interrelated mecha-
nisms: 1) inhibition of the direct vasoconstrictive effect of
renal TxA2 on the afferent arterioles and mesangial cells; 2)
enhancement of vasodilating PG synthesis due to the increased
availability of arachidonic acid endoperoxides (PGG2 and
PGH2) for renal formation of PGE2 and PGI2; and 3)
reduction of the tubulo-glomerular feedback activation.
To our knowledge, no study has addressed the problem of
picotamide action directly on the single nephron. Therefore,
we cannot exclude the possibility that the natriuretic,
kaliuretic, and diuretic effects of picotamide may have been
partly due to some direct picotamide tubular action.
Study limitations. It is not possible to transfer the results
obtained in our trials to all patients with heart failure,
especially those who are usually treated with aspirin and/or
ACE inhibitors. Such patients were excluded from the
study, as were those patients with serious renal dysfunction
(i.e., patients with creatinine 2 mg/dl). This latter com-
plication can confound the evaluation of renal function after
picotamide administration.
Conclusions. Our results suggest that increased renal
TxA2 formation is an important component of the complex
pathophysiology of heart failure and that inhibition of renal
thromboxane activity notably improves kidney function.
However, no conclusions can be drawn regarding the use of
Figure 2. Effects of thromboxane A2 inhibition on renal hemodynamics. Open bars  placebo; hatched bars  active treatment. *p  0.05 vs. day 8 of
placebo; **p  0.01 vs. day 8 of placebo. ERPF  effective renal plasma flow; FF  filtration fraction; GFR  glomerular filtration rate; RVR  renal
vascular resistance.
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TxA2 inhibitors in the treatment of CHF. To do so, clinical
trials must be expressly designed to address this aspect.
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